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Purpose: Lipoprotein-associated phospholipase A2 (Lp-PLA2) is an inflammatory 
enzyme expressed in atherosclerotic plaques. We investigated the association of cir-
culating Lp-PLA2 with characteristics of vulnerable coronary atherosclerotic 
plaques. Materials and Methods: We recruited 113 patients with either unstable 
angina (UA, n=59) and stable angina (SA, n=54) by coronary angiography. Thirty-
six healthy subjects served as controls. Intravascular ultrasound (IVUS) was used to 
evaluate the characteristics of coronary atherosclerotic plaque, and serum Lp-PLA2 
concentration was measured as well. Results: Lp-PLA2 concentration was signifi-
cantly higher in both UA and SA patients [(396±36) μg/L and (321±39) μg/L, re-
spectively] compared with the controls [(127±49) μg/L, p<0.01], and higher in UA 
than SA group. IVUS findings showed that remodeling index (RI) (0.91±0.15 vs. 
0.85±0.11, p=0.005) and eccentricity index (EI) (0.73±0.16 vs. 0.65±0.22, p=0.039) 
were larger in UA than in SA group, and fibrous caps were thicker in SA than UA 
group [(0.91±0.23) mm vs. (0.63±0.21) mm, p=0.032]. Moreover, Lp-PLA2 corre-
lated positively with EI (r=0.439, p<0.01) and RI (r=0.592, p<0.05) in UA group. 
There was an inverse relationship between Lp-PLA2 and fibrous cap thickness in 
both UA (r=-0.587, p<0.001) and SA (r=-0.318, p<0.05) groups. The independent 
risk factors in UA group were Lp-PLA2 (OR=1.055, 95% CI: 1.03-1.08, p=0.013), 
LDL-cholesterol (OR=0.032, 95% CI: 0.00-0.05, p=0.041) and fibrous cap thick-
ness (OR=0.008, 95% CI: 0.00-0.45, p=0.019). Lp-PLA2 was strongly associated 
with both EI and fibrous cap thickness in both groups. Conclusion: Serum level of 
Lp-PLA2 is associated with both eccentricity index and fibrous cap thickness in 
both UA and SA groups. Elevated levels of circulating Lp-PLA2 might to be a 
strong risk factor and more serious for unstable angina than stable angina.
Key Words:    Vulnerable plaque, lipoprotein-associated phospholipase A2, athero-
sclerosis
INTRODUCTION
Accumulating evidence indicates that inflammation is recognized to play an im-Association of Lp-PLA2 with Vulnerable Coronary Atherosclerotic Plaque
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during the course of coronary catheterization. In addition, 
36 healthy subjects with a mean age of (57.9±10.9) (37-75) 
years served as controls. Written informed consent was ob-
tained from patients and controls, and the research proto-
cols were approved by the Institutional Board of the Sec-
ond Hospital of Shandong University. 
SA was defined as no changes in angina symptoms in 
terms of frequency, duration, or intensity in the preceding 
four weeks with normal cardiac enzymes and UA was de-
fined as accelerated angina, new-onset severe angina, or an-
gina at rest within four weeks, with electrocardiographic 
changes of ischemia (ST-segment depression or elevation 
of at least 1 mm) or a less than two-fold increase in levels 
of cardiac enzymes or abnormal cardiac troponin I and/or 
T. For all study groups, the exclusion criteria were acute 
myocardial infarction, chronic total occlusions, severe an-
gular, calcific or diffuse lesions in the culprit artery, acute 
infection or autoimmune diseases, previous percutaneous 
coronary interventions or coronary artery bypass graft, val-
vular heart disease, congestive heart failure (LVEF<30%), 
malignant tumors, and severe liver disease (plasma alanine 
aminotransferase level >120U/L). Major Adverse Cardio-
vascular Events (MACE) including acute ST-elevation myo-
cardial infarction, revascularization, or even cardiovascular 
death were followed for about 18 months. The patient pop-
ulation was stratified according to ACS status.11
IVUS imaging
IVUS examination (with a 2.9F, 40 MHz mechanical trans-
ducer, Boston Scientific Galaxy I, Minneapolis, MN, USA) 
was performed during angiography. The IVUS catheter was 
advanced distal to the target lesion, and imaging was re-
corded retrograde to the aorto-ostial junction at an automat-
ic pullback speed of 0.5 mm/s. In addition, the culprit lesion 
was discussed with manual interrogation. Quantitative IVUS 
analysis was performed by use of planimetry software. Of-
fline qualitative and quantitative analyses of IVUS images 
were performed by two independent experienced IVUS in-
vestigators, blinded to clinical data, following the American 
College of Cardiology Clinical Expert Consensus Docu-
ment on Standards for Acquisition,12 Measurement and Re-
porting of IVUS Studies. 
The proximal or distal reference sites and the culprit le-
sion site were identified in the target vessel. Proximal and 
distal references were the single slices with largest lumen 
and smallest plaque burden within 10 mm proximally and 
distally, but before any large side branch and the culprit le-
portant role in atherosclerosis, atherosclerotic plaque pro-
gression, or even predisposing vulnerable plaque to rupture.1 
Peripheral blood biomarkers of inflammation have been as-
sociated with incident and recurrent cardiac events. Inflam-
matory cells, cytokines and other biomolecules are implicat-
ed in these processes, and have, therefore, been investigated 
as potential markers of atherosclerotic plaque progression 
and cardiovascular disease risk. The levels of plasma mark-
ers of inflammation such as C-reactive protein are elevated 
in coronary heart disease, especially acute coronary syn-
drome.2
Recent studies show that lipoprotein-associated phospho-
lipase A2 (Lp-PLA2) is an independent predictor of coronary 
heart disease,3 expressed by inflammatory cells in athero-
sclerotic plaques which hydrolyses oxidised phospholipids 
to yield pro-inflammatory products implicated in endothelial 
dysfunction, plaque inflammation, and formation of necrotic 
core in plaque, thus postulating a link between oxidative 
modification of low-density lipoprotein (LDL)-cholesterol 
and development of inflammatory responses in the arterial 
intima.4,5 Two thirds of plasma Lp-PLA2 are bound to LDL-
cholesterol molecules, whereas the remainder is distributed 
between LDL-cholesterol and very low density lipopro-
teins.5-7 Lp-PLA2 is expressed abundantly in the necrotic 
core of atherosclerosis plaque, and its’ enzymatic products 
participate in the process of inflammation and cell death, 
rendering plaque vulnerable to rupture.8-10 
Considering a potential need for inflammatory biomark-
ers, we aimed to explore the association of Lp-PLA2 with 
characteristics of vulnerable coronary atherosclerotic plaques 
in patients with coronary heart disease by examining the re-
lationships between serum levels of Lp-PLA2 and the pa-
rameters obtained by intravascular ultrasound (IVUS).
MATERIALS AND METHODS
　　　
Study subjects
A total of 113 patients were recruited, and all patients were 
approved by the Ethics Committee of Shandong University. 
The range of age was 35-81 years (mean age 58.2±10.6 
years); 58 were male and 55 were female. These patients 
were diagnosed as stable angina (SA, 54 cases) or unstable 
angina (UA, 59 cases), showing a segmental stenosis with 
20% to 70% lumen diameter reduction in one major coro-
nary artery and at least 2.25 mm in diameter on coronary 
angiography. IVUS examinations were performed as well Yu-Sheng Liu, et al.
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Details regarding other biomarkers are provided in the on-
line data supplement. 
Data analysis
Statistical analysis was performed using SPSS software 
(version 13.0, SPSS Inc., Chicago, IL, USA). Data were re-
ported as mean values±one SD and first tested for normali-
ty of distribution by the Shapiro-Wilk test. Comparisons of 
categorical and continuous variables were performed by 
chi-square or Fisher’s exact test. Relationship among vari-
ables was appropriately tested using Pearson correlation 
test or Spearman rank order correlation test. Cardiovascular 
risk factors of unstable angina by multiple logistic regres-
sion analysis and the association between Lp-PLA2 concen-
tration and parameters obtained by IVUS were tested by 
linear regression analysis. A two-tailed p-value <0.05 was 
considered to be statistically significant.
 
RESULTS
 
Patient characteristics
The baseline characteristics of UA and SA patients are pre-
sented in Table 1. Three experienced observers reviewed 
patients’ clinical and angiographic data to ascertain degree 
of coronary stenosis and angina status, respectively. No sig-
nificant differences exist in the use of angiotension-convert-
ing enzyme inhibitors/angiotensin-receptor blockers, beta-
blockers, calcium channel blockers, statins, anti-platelet 
agents and nitrates between the two groups.
Serum levels of Lp-PLA2
Baseline concentrations of serum Lp-PLA2 were significantly 
higher in UA and SA patients [(396±36) μg/L and (321±39) 
μg/L, respectively] as compared with that of controls 
[(127±49) μg/L, p<0.01]. And serum concentrations of Lp-
PLA2 were higher in UA group than in SA group (Fig. 1).
IVUS findings
At the culprit lesion site, minimum lumen area, EEM CSA, 
and lumen area stenosis had no significant differences be-
tween UA and SA groups. Parameters of proximal and dis-
tal reference vessels were similar between the two groups. 
However, plaque area [(7.83±2.81) mm2 vs. (6.52±2.91) 
mm2, p=0.026], RI (0.91±0.15 vs. 0.85±0.11, p=0.005) and 
EI (0.73±0.16 vs. 0.65±0. 22, p=0.039) were larger in UA 
group than in SA group, whereas fibrous caps were thicker in 
sion site was defined as the image slice with smallest lumen 
cross sectional area (CSA). The external elastic membrane 
(EEM) CSA was measured by tracing the leading edge of 
the media-adventitia boundary and lumen CSA was deter-
mined by tracing the boundary between the lumen and the 
intimal leading edge. Plaque area (EEM CSA-lumen CSA), 
plaque burden (plaque area/EEM CSA), and lumen area 
stenosis [(reference lumen CSA-minimum lumen CSA)/
reference lumen CSA] was calculated. 
The maximal and minimal thickness of the vessel wall 
was measured, and the atheroma eccentricity index (EI) 
[(maximum plaque thickness-minimum plaque thickness) /
maximum plaque thickness] was then calculated at the cul-
prit lesion site. EI <0.5 or ≥0.5 was respectively defined as 
concentric or eccentric plaque. Eccentric plaque seems to 
be more vulnerable than concentric because eccentric 
plaque is likely to rupture by various intra-luminal stresses. 
Coronary artery remodeling index (RI) was usually calcu-
lated as: the EEM CSA at the minimal lesion site/average 
EEM CSA at the proximal and distal reference sites. Posi-
tive remodeling, intermediate remodeling and negative re-
modeling were described as RI >1.05, 0.95-1.05, and 
<0.95, respectively. 
The atherosclerotic lesion with positive remodeling has 
usually a larger lipid core, and is more vulnerable. Plaques 
were classified into soft, fibrous, calcific and mixed plaques 
seperately according to the characteristics of the IVUS im-
ages.12 The echolucent zone in a plaque on IVUS may dem-
onstrate a lipid-rich core. Soft plaque is considered as a vul-
nerable plaque due to fibrous cap unformed. Vulnerability 
index here includes all the variables analyzed by IVUS, es-
pecially RI, EI, positive remodeling, soft plaque and fibrous 
cap thickness. Large lipid core, thin fibrous cap, large intra-
plaque hemorrhage might imply highly unstable coronary 
events.13
Measurement of serum Lp-PLA2 
Biochemical analyses was performed in blinded arrange-
ment. Fasting blood samples were centrifuged at 1,500×g 
for 10 minutes at 4°C, then stored at -80°C before use. Plas-
ma cholesterol, triglyceride, high-density lipoprotein (HDL), 
low-density lipoprotein (LDL), fasting blood glucose, cre-
atinine, uric acid and fibrinogen were tested by a biochemi-
cal analyser (Hitachi-7600, Tokyo, Japan). The intra- and 
inter-assay coefficients of variation were <5%. Serum Lp-
PLA2 was measured by a colorimetric method with an intra-
assay precision of 1.7% and inter-assay precision of 4.8%. Association of Lp-PLA2 with Vulnerable Coronary Atherosclerotic Plaque
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Correlations of Lp-PLA2 concentration with coronary 
atherosclerotic plaque characteristics
Serum level of Lp-PLA2 correlated positively with eccen-
tricity index (r=0.439, p<0.01) (Fig. 4A.) and remodeling 
index (r=0.592, p<0.05) (Fig. 4B.) in UA group. There was 
an inverse relationship between the serum level of Lp-PLA2 
and the fibrous cap thickness in both UA (r=-0.587, 
SA group than in UA group [(0.91±0.23) mm vs. (0.63±0.21) 
mm, p=0.032]. Moreover, positive remodeling was more fre-
quent in UA group than in the SA group (29% vs. 10%, 
p=0.021), and negative remodeling was less in UA group 
than in SA group (55% vs. 77%, p=0.016). Parameters from 
IVUS findings are shown in Table 2. Part of results by coro-
nary angiography and IVUS are showed in Fig. 2 and 3. 
  
Multiple logistic regression analysis of cardiovascular 
risk factors for the patients with unstable angina
Multiple logistic regression analysisshowed that the inde-
pendent cardiovascular risk factors of the patients with un-
stable angina were serum levels of Lp-PLA2 (OR=1.055, 
95% CI: 1.03-1.08, p=0.013), LDL-cholesterol (OR=0.032, 
95% CI: 0.00-0.05, p=0.041) and fibrous cap thickness 
(OR=0.008, 95% CI: 0.00-0.45, p=0.019). Although there 
was no signaficant difference between the two groups in-
cluding age, gender, BMI, hypertension, total cholesterol, 
triglyceride, HDL-cholesterol, fasting blood glucose, creati-
nine, urine acid and fibrinogen they were conventional risk 
predictors (Table 3).
Table 1. Clinical Characteristics of the Patients
Variables UA (n=59) SA (n=54) p value
Age (yrs)   58.2±10.6   58.3±10.8 0.986
Male [n (%)] 58 (51) 55 (49) 0.143
Body mass index (kg/m
2) 26.50±2.46 26.10±2.70 0.456
Hypertension [n (%)] 49 (43) 43 (38) 0.851
Diabetes [n (%)] 21 (19) 11 (10) 0.318
Smoker [n (%)] 33 (29) 30 (27) 0.196
Total cholesterol (mmol/L)   4.68±0.90   4.57±1.28 0.758
Triglyceride (mmol/L)   1.98±0.99   2.09±1.36 0.355
HDL-cholesterol (mmol/L)   1.01±0.12   0.98±0.15 0.213
LDL-cholesterol (mmol/L)   2.98±0.89   2.85±1.19 0.543
Fasting blood glucose (mmol/L)   5.83±1.52   5.51±1.16 0.273
Creatinine (μmol/L) 73.34±9.92 71.90±9.55 0.463
Urine acid (μmol/L) 351.62±84.37 349.98±84.96 0.877
Fibrinogen (g/L)   2.84±0.68   2.86±0.67 0.873
Target vessel [n (%)]
    LAD 62 (55) 49 (43) 0.219
    LCX 34 (30) 32 (29) 0.847
    RCA 17 (15) 34 (30) 0.128
Medications [n (%)]
   Anti-platelet agents 57 (96) 50 (92) 0.781
   Beta-blockers 38 (65) 37 (70) 0.315
   Statins 41 (71) 40 (75) 0.358
   ACE inhibitors/ARB 16 (28) 10 (19) 0.329
   Calcium channel blockers 19 (32) 12 (22) 0.365
   Nitrates 22 (38) 12 (23) 0.126
UA, unstable angina; SA, stable angina; HDL, high-density lipoprotein; LDL, low-density lipoprotein; LAD, left anterior descending coronary 
artery; LCX, left circumflex artery; RCA, right coronary artery; ACE, angiotension-converting enzyme; ARB, angiotensin-receptor blocker.  
Fig. 1. Serum concentions of Lp-PLA2 in control subjects, SA group, and UA 
group. *p<0.01, compared with control. †p=0.014, compared with SA group. 
Lp-PLA2, lipoprotein-associated phospholipase A2; SA, stable angina; UA, 
unstable angina. 
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Table 2. IVUS Image Analyses for Minimal Lumen Site
Variables UA (n=59) SA (n=54) p value
EEM CSA (mm
2) 12.93±4.31 12.14±3.89 0.368
MLA (mm
2)   5.05±2.38   5.61±3.01 0.315
Plaque area (mm
2)   7.83±2.81   6.52±2.91 0.026
Lumen area stenosis (%)   49.01±11.58   46.16±16.07 0.331
Remodeling index   0.91±0.15   0.85±0.11 0.005
Eccentricity index    0.73±0.16   0.65±0.22 0.039
Eccentric lesion [n (%)] 52 (89) 38 (71) 0.023
Positive remodeling [n (%)] 17 (29)   5 (10) 0.021
Negative remodeling [n (%)] 32 (55) 42 (77) 0.016
Soft plaque [n (%)] 19 (32)   9 (16) 0.069
Fibrous cap (mm)   0.63±0.21   0.91±0.23 0.032
IVUS, intravascular ultrasound; UA, unstable angina; SA, stable angina; EEM, external elastic membrane; CSA, cross-sectional area; 
MLA, minimum lumen area.
Table 3. Multiple Logistic Regression Analysis of Cardiovascular Risk Factors for Unstable Angina
Variables OR 95% CI p value
Age (yrs) 1.049 0.97-1.13 0.207
Male 0.999 0.99-0.10 0.132
Body mass index 1.002 0.93-1.06 0.957
Hypertension 0.997 0.98-1.01 0.761
Total cholesterol 0.901 0.66-1.22 0.083
Triglyceride 0.781 0.60-1.01 0.952
HDL-cholesterol 0.863 0.48-1.54 0.913
LDL-cholesterol 0.032 0.00-0.05 0.041
Lp-PLA2 1.055 1.03-1.08 0.013
Fasting blood glucose 0.900 0.76-1.06 0.207
Creatinine 1.795 0.74-4.35 0.193
Urine acid 0.991 0.31-3.12 0.921
Fibrinogen 0.979 0.95-1.00 0.132
Remodeling index 0.008 0.00-1.53 0.071
Eccentricity index 0.586    0.11-32.14 0.793
Fibrous cap 0.008 0.00-0.45 0.019
OR, odds ratio; CI, confidence interval; HDL, high-density lipoprotein; LDL, low-density lipoprotein; Lp-PLA2, lipoprotein-associated phos-
pholipase A2.
Fig. 2. Coronary angiography shows (A) single coronary lesion and (B) multiple coronary lesions.
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observed throughout the spectrum of atherosclerotic disease, 
from initial lesion formation to plaque destabilization or rup-
ture, inflammation plays a primary role in the progression of 
atherosclerosis.14 The key role of inflammation is evidenced 
by numerous epidemiology studies to indicate the existence 
of inflammatory cells in the cap of atherosclerotic plaques3,10 
and an association between circulating inflammatory mark-
ers (e.g., C-reactive protein, interleukin-6).2,15 
Lp-PLA2, known as platelet-activating factor acetylhydro-
lase, is a 50 kDa, Ca2+ independent enzyme associated with 
LDL- cholesterol. The enzyme is a member of a growing 
family of phospholipases A2 and secreted mainly by macro-
phages/monocytes, mast cells, and T lymphocytes.5,6,16 
Kolodgie, et al.10 found the key role of macrophages in fi-
brous cap thickness and necrotic core expansion, along with 
relationship between macrophages and Lp-PLA2 expression 
in the fibrous cap region, which indicated that Lp-PLA2 is in-
volved in plaque vulnerability, particularly in the progression 
spanning from thin-cap fibroatheromas to plaque rupture. 
Rosenson17 demonstrated that circulating Lp-PLA2 is a novel 
inflammatory biomarker and additive to traditional risk fac-
tors for atherogenesis. Rosenson, however, measured only 
circulating levels of Lp-PLA2 (Lp-PLA2 mass), but not Lp-
PLA2 activity, because previously studies4,18 demonstrated 
that Lp-PLA2 activity and mass are positively associated with 
each other.
In agreement with the findings by Kolodgie, et al.10 and 
p<0.001) and SA groups (r=-0.318, p<0.05). Serum Lp-
PLA2 did not correlate with other IVUS parameters in ei-
ther group.
Association of Lp-PLA2 with eccentricity index, 
remodeling index and fibrous cap thickness by multiple 
linear regression analysis
Serum level of Lp-PLA2 was strongly associated with both 
eccentricity index and fibrous cap thickness in both UA and 
SA groups. And fibrous cap thickness, the first of the three 
variables in either UA group (β=-0.408, p<0.001) or SA 
group (β=-0.337, p=0.008) was associated negatively with 
Lp-PLA2. However, remodeling index was associated with 
Lp-PLA2 only in UA group (β=0.356, p=0.001), but not in 
SA group (β=0.236, p=0.072) (Table 4).
Follow-up results
During the follow-up period of more than 1.5 years, 5 
(8.47%) patients in the UA group and 3 (5.55%) patients in 
the SA group underwent revascularization (p>0.05). No 
other major adverse cardiovascular events (MACE) such as 
SCD occurred in either group.
DISCUSSION
According to the local and systemic inflammatory responses 
Table 4. Multiple Linear Regression Analysis of Variables with Lp-PLA2 Concentration
Variables
SA (n=54) UA (n=59)
β t p β t p
Remodeling index 0.236 1.840 0.072 0.356 3.612 0.001
Eccentricity index 0.268 2.082 0.042 0.278 3.016 0.004
Fibrous cap  -0.337 -2.754 0.008 -0.408 -4.264 0.000
Lp-PLA2, lipoprotein-associated phospholipase A2.
Standardized coefficients β.
Fig. 3. IVUS image of control shows one patient with chest pain and no stenosis found by coronary angiography; compared with SA 
group, IVUS image of UA group shows vulnerable plaque. IVUS, intravascular ultrasound; SA, stable angina; UA, unstable angina. 
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Packard, et al.3 our results showed that Lp-PLA2 concentra-
tion was significantly increased in UA and SA patients, and 
that it was higher in UA group, suggesting that higher level 
of Lp-PLA2 is correlated with some morphologic variables 
indicative of vulnerable plaques, and that larger atheroscle-
rotic burden may be useful for the recognition of high-risk 
patients. Major novelties of the current study include the 
correlation of higher concentration of Lp-PLA2 with the in-
creased remodeling index and eccentricity index in UA pa-
tients, evidenced by IVUS in vivo, but not in SA patients, 
and an inverse relationship between the concentration of 
Lp-PLA2 and the fibrous cap thickness in both groups. Data 
from IVUS findings showed that plaque area, remodeling 
index, and eccentricity index were larger in UA group than 
those in SA group. Moreover, fibrous caps were thicker in 
SA patients than in UA patients. Therefore, positive remod-
eling was more frequent in UA group than in SA group, and 
negative remodeling was less in UA patients. The above ob-
servations together show that higher concentration of Lp-
PLA2 imply more serious coronary atherosclerosis and may 
be prone to high-risk or vulnerable coronary plaques in an-
gina patients, especially in UA patients. These data are in 
accordance with the histopathological findings by Kolodg-
ie, et al.10 that macrophages and Lp-PLA2 expression in the 
fibrous cap region may indicate that Lp-PLA2 is involved in 
plaque vulnerability, particularly in the progression from 
thin-cap fibroatheromas to plaque rupture. Our findings 
suggested that Lp-PLA2 was released into circulation in the 
process of atherosclerosis and involved in the activity and 
vulnerability of atherosclerotic plaque.   
The vulnerable plaque, rather than the degree of luminal 
narrowing, is a major factor contributing to acute coronary 
syndrome, which has been clarified by pathologic studies.19 
The main components of most vulnerable plaques are usu-
ally thin fibrous cap, large lipid pool and active inflamma-
tion.20 Larger plaque area and positive remodeling are seen 
frequently in acute coronary syndrome, on the contary, 
smaller plaque area and negative remodeling are often linked 
to SA.20,21 Our study indicated that UA patients had higher 
RI, eccentricity index, larger plaque area and plaque bur-
den, and more positive remodeling and eccentric plaques, in-
dicating a close relationship between angina status and the 
plaque morphology. In addition, these findings validate the 
diagnostic value of Lp-PLA2 as a specific biomarker to dif-
ferentiate unstable angina patients with a high risk of vul-
nerable coronary atherosclerotic plaques from stable angina 
and provide further evidence for its potential applicability 
Fig. 4. Correlation of serum level of Lp-PLA2 with eccentricity index (A), re-
modeling index (B) and fibrous cap (C) in UA and SA groups. Solid line, fit 
line for UA group; dotted line, fit line for SA group. UA, unstable angina; SA, 
stable angina.
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in clinical practice.
In summary, the present findings indicate an association 
of Lp-PLA2 expression and advanced ruptured and rupture-
prone lesions as thin-cap fibroatheromas. We obtained the 
parameters of coronary atherosclerotic plaque by IVUS in 
vivo and serum levels of Lp-PLA2. The results can reflect 
the relation between Lp-PLA2 and eccentricity index and fi-
brous cap thickness. Although the findings from the present 
study are intriguing and suggest biologic plausibility and 
specificity to vascular inflammation, a causal role of Lp-
PLA2 in the progression of atherosclerosis and plaque vul-
nerability will likely requires further research.
Study limitations
This was an exploratory study that used novel imaging 
IVUS modalities to assess plaque composition and charac-
teristic. Lp-PLA2 activity was not determined, and the clini-
cal relevance of plaque stability observed with serum Lp-
PLA2 requires a larger sample size. This study focused on a 
small segment of the coronary arterial tree and limited, and 
it might not fully represent disease progression elsewhere. 
Finally, the approach undertaken in this and other IVUS tri-
als did not assess changes in the precise plaque phenotype 
that may portend clinical risk. 
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